Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Clinical trial design for cutaneous neurofibromas.

Cannon A, Jarnagin K, Korf B, Widemann BC, Casey D, Ko HS, Blakeley JO, Verma SK, Pichard DC.

Neurology. 2018 Jul 10;91(2 Supplement 1):S31-S37. doi: 10.1212/WNL.0000000000005790.

PMID:
29987133
2.

Considerations for development of therapies for cutaneous neurofibroma.

Verma SK, Riccardi VM, Plotkin SR, Weinberg H, Anderson RR, Blakeley JO, Jarnagin K, Lee J.

Neurology. 2018 Jul 10;91(2 Supplement 1):S21-S30. doi: 10.1212/WNL.0000000000005791.

PMID:
29987132
3.

Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target.

Long T, Rojo-Arreola L, Shi D, El-Sakkary N, Jarnagin K, Rock F, Meewan M, Rascón AA Jr, Lin L, Cunningham KA, Lemieux GA, Podust L, Abagyan R, Ashrafi K, McKerrow JH, Caffrey CR.

PLoS Negl Trop Dis. 2017 Jul 13;11(7):e0005680. doi: 10.1371/journal.pntd.0005680. eCollection 2017 Jul.

4.

Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.

Dong C, Virtucio C, Zemska O, Baltazar G, Zhou Y, Baia D, Jones-Iatauro S, Sexton H, Martin S, Dee J, Mak Y, Meewan M, Rock F, Akama T, Jarnagin K.

J Pharmacol Exp Ther. 2016 Sep;358(3):413-22. doi: 10.1124/jpet.116.232819. Epub 2016 Jun 27.

PMID:
27353073
5.

Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.

Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Gold LS.

Immunotherapy. 2016 Jul;8(8):853-66. doi: 10.2217/imt-2016-0023. Epub 2016 Jun 10. Review.

6.

Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.

Jarnagin K, Chanda S, Coronado D, Ciaravino V, Zane LT, Guttman-Yassky E, Lebwohl MG.

J Drugs Dermatol. 2016 Apr;15(4):390-6. Review.

PMID:
27050693
7.

Discovery and structure-activity relationships of 6-(benzoylamino)benzoxaboroles as orally active anti-inflammatory agents.

Akama T, Dong C, Virtucio C, Freund YR, Chen D, Orr MD, Jacobs RT, Zhang YK, Hernandez V, Liu Y, Wu A, Bu W, Liu L, Jarnagin K, Plattner JJ.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5870-3. doi: 10.1016/j.bmcl.2013.08.096. Epub 2013 Sep 6.

PMID:
24075731
8.

Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors.

Akama T, Dong C, Virtucio C, Sullivan D, Zhou Y, Zhang YK, Rock F, Freund Y, Liu L, Bu W, Wu A, Fan XQ, Jarnagin K.

J Pharmacol Exp Ther. 2013 Dec;347(3):615-25. doi: 10.1124/jpet.113.207662. Epub 2013 Sep 18.

PMID:
24049062
9.

Structure-activity relationships of 6-(aminomethylphenoxy)-benzoxaborole derivatives as anti-inflammatory agent.

Akama T, Virtucio C, Dong C, Kimura R, Zhang YK, Nieman JA, Sharma R, Lu X, Sales M, Singh R, Wu A, Fan XQ, Liu L, Plattner JJ, Jarnagin K, Freund YR.

Bioorg Med Chem Lett. 2013 Mar 15;23(6):1680-3. doi: 10.1016/j.bmcl.2013.01.072. Epub 2013 Jan 29.

PMID:
23411072
10.

Inhibition of Toll-like receptor-mediated inflammation in vitro and in vivo by a novel benzoxaborole.

Dong C, Sexton H, Gertrudes A, Akama T, Martin S, Virtucio C, Chen CW, Fan X, Wu A, Bu W, Liu L, Feng L, Jarnagin K, Freund YR.

J Pharmacol Exp Ther. 2013 Feb;344(2):436-46. doi: 10.1124/jpet.112.200030. Epub 2012 Nov 28.

PMID:
23192653
11.

Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center.

Freund YR, Akama T, Alley MR, Antunes J, Dong C, Jarnagin K, Kimura R, Nieman JA, Maples KR, Plattner JJ, Rock F, Sharma R, Singh R, Sanders V, Zhou Y.

FEBS Lett. 2012 Sep 21;586(19):3410-4. doi: 10.1016/j.febslet.2012.07.058. Epub 2012 Jul 25.

12.

Early rapid identification of in vivo rat metabolites of AN6414, a novel boron-containing PDE4 inhibitor by QTRAP LC/MS/MS to support drug discovery.

Bu W, Akama T, Chanda S, Sullivan D, Ciaravino V, Jarnagin K, Freund Y, Sanders V, Chen CW, Fan X, Heyman I, Liu L.

J Pharm Biomed Anal. 2012 Nov;70:344-53. doi: 10.1016/j.jpba.2012.05.024. Epub 2012 May 28.

PMID:
22687459
13.
14.

Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis.

Nare B, Wring S, Bacchi C, Beaudet B, Bowling T, Brun R, Chen D, Ding C, Freund Y, Gaukel E, Hussain A, Jarnagin K, Jenks M, Kaiser M, Mercer L, Mejia E, Noe A, Orr M, Parham R, Plattner J, Randolph R, Rattendi D, Rewerts C, Sligar J, Yarlett N, Don R, Jacobs R.

Antimicrob Agents Chemother. 2010 Oct;54(10):4379-88. doi: 10.1128/AAC.00498-10. Epub 2010 Jul 26.

15.

Use of diagnostic accuracy as a metric for evaluating laboratory proficiency with microarray assays using mixed-tissue RNA reference samples.

Pine PS, Boedigheimer M, Rosenzweig BA, Turpaz Y, He YD, Delenstarr G, Ganter B, Jarnagin K, Jones WD, Reid LH, Thompson KL.

Pharmacogenomics. 2008 Nov;9(11):1753-63. doi: 10.2217/14622416.9.11.1753.

16.

The liver pharmacological and xenobiotic gene response repertoire.

Natsoulis G, Pearson CI, Gollub J, P Eynon B, Ferng J, Nair R, Idury R, Lee MD, Fielden MR, Brennan RJ, Roter AH, Jarnagin K.

Mol Syst Biol. 2008;4:175. doi: 10.1038/msb.2008.9. Epub 2008 Mar 25.

17.
18.

Use of a mixed tissue RNA design for performance assessments on multiple microarray formats.

Thompson KL, Rosenzweig BA, Pine PS, Retief J, Turpaz Y, Afshari CA, Hamadeh HK, Damore MA, Boedigheimer M, Blomme E, Ciurlionis R, Waring JF, Fuscoe JC, Paules R, Tucker CJ, Fare T, Coffey EM, He Y, Collins PJ, Jarnagin K, Fujimoto S, Ganter B, Kiser G, Kaysser-Kranich T, Sina J, Sistare FD.

Nucleic Acids Res. 2005 Dec 23;33(22):e187.

19.

A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity.

Fielden MR, Eynon BP, Natsoulis G, Jarnagin K, Banas D, Kolaja KL.

Toxicol Pathol. 2005;33(6):675-83.

PMID:
16239200
20.

Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.

Ganter B, Tugendreich S, Pearson CI, Ayanoglu E, Baumhueter S, Bostian KA, Brady L, Browne LJ, Calvin JT, Day GJ, Breckenridge N, Dunlea S, Eynon BP, Furness LM, Ferng J, Fielden MR, Fujimoto SY, Gong L, Hu C, Idury R, Judo MS, Kolaja KL, Lee MD, McSorley C, Minor JM, Nair RV, Natsoulis G, Nguyen P, Nicholson SM, Pham H, Roter AH, Sun D, Tan S, Thode S, Tolley AM, Vladimirova A, Yang J, Zhou Z, Jarnagin K.

J Biotechnol. 2005 Sep 29;119(3):219-44.

PMID:
16005536
21.

Classification of a large microarray data set: algorithm comparison and analysis of drug signatures.

Natsoulis G, El Ghaoui L, Lanckriet GR, Tolley AM, Leroy F, Dunlea S, Eynon BP, Pearson CI, Tugendreich S, Jarnagin K.

Genome Res. 2005 May;15(5):724-36.

22.

Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast.

Perkins E, Sun D, Nguyen A, Tulac S, Francesco M, Tavana H, Nguyen H, Tugendreich S, Barthmaier P, Couto J, Yeh E, Thode S, Jarnagin K, Jain A, Morgans D, Melese T.

Cancer Res. 2001 May 15;61(10):4175-83.

23.

Differential Distribution of Bradykinin B(2) Receptors in the Rat and Human Cardiovascular System.

Figueroa CD, Marchant A, Novoa U, Förstermann U, Jarnagin K, Schölkens B, Müller-Esterl W.

Hypertension. 2001 Jan;37(1):110-120.

PMID:
11208765
24.

Structure-based design of six novel classes of nonpeptide antagonists of the bradykinin B2 receptor.

Artis DR, Brotherton-Pleiss C, Pease JH, Lin CJ, Ferla SW, Newman SR, Bhakta S, Ostrelich H, Jarnagin K.

Bioorg Med Chem Lett. 2000 Nov 6;10(21):2421-5.

PMID:
11078192
25.

Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle.

Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead GS, Lapierre JM, Dankwardt J, Morgans D Jr, Wilhelm R, Jarnagin K.

J Biol Chem. 2000 Aug 18;275(33):25562-71.

26.

Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2.

Jarnagin K, Grunberger D, Mulkins M, Wong B, Hemmerich S, Paavola C, Bloom A, Bhakta S, Diehl F, Freedman R, McCarley D, Polsky I, Ping-Tsou A, Kosaka A, Handel TM.

Biochemistry. 1999 Dec 7;38(49):16167-77.

PMID:
10587439
27.

Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2.

Hemmerich S, Paavola C, Bloom A, Bhakta S, Freedman R, Grunberger D, Krstenansky J, Lee S, McCarley D, Mulkins M, Wong B, Pease J, Mizoue L, Mirzadegan T, Polsky I, Thompson K, Handel TM, Jarnagin K.

Biochemistry. 1999 Oct 5;38(40):13013-25.

PMID:
10529171
28.

Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B.

Paavola CD, Hemmerich S, Grunberger D, Polsky I, Bloom A, Freedman R, Mulkins M, Bhakta S, McCarley D, Wiesent L, Wong B, Jarnagin K, Handel TM.

J Biol Chem. 1998 Dec 11;273(50):33157-65.

29.

Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.

Saldou N, Obernolte R, Huber A, Baecker PA, Wilhelm R, Alvarez R, Li B, Xia L, Callan O, Su C, Jarnagin K, Shelton ER.

Cell Signal. 1998 Jun;10(6):427-40.

PMID:
9720765
30.

Purification and physical characterization of cloned human cAMP phosphodiesterases PDE-4D and -4C.

Saldou N, Baecker PA, Li B, Yuan Z, Obernolte R, Ratzliff J, Osen E, Jarnagin K, Shelton ER.

Cell Biochem Biophys. 1998;28(2-3):187-217.

PMID:
9515166
31.

Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis.

Obernolte R, Ratzliff J, Baecker PA, Daniels DV, Zuppan P, Jarnagin K, Shelton ER.

Biochim Biophys Acta. 1997 Sep 12;1353(3):287-97.

PMID:
9349724
32.

Mutations in the B2 bradykinin receptor reveal a different pattern of contacts for peptidic agonists and peptidic antagonists.

Jarnagin K, Bhakta S, Zuppan P, Yee C, Ho T, Phan T, Tahilramani R, Pease JH, Miller A, Freedman R.

J Biol Chem. 1996 Nov 8;271(45):28277-86.

33.

The N-terminal amino group of [Tyr8]bradykinin is bound adjacent to analogous amino acids of the human and rat B2 receptor.

AbdAlla S, Jarnagin K, Müller-Esterl W, Quitterer U.

J Biol Chem. 1996 Nov 1;271(44):27382-7.

34.

Na+ ions binding to the bradykinin B2 receptor suppress agonist-independent receptor activation.

Quitterer U, AbdAlla S, Jarnagin K, Müller-Esterl W.

Biochemistry. 1996 Oct 15;35(41):13368-77.

PMID:
8873604
35.

Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies.

abu Alla S, Quitterer U, Grigoriev S, Maidhof A, Haasemann M, Jarnagin K, Müller-Esterl W.

J Biol Chem. 1996 Jan 19;271(3):1748-55.

36.

Cloning and functional expression of the cDNA encoding rat lanosterol 14-alpha demethylase.

Sloane DL, So OY, Leung R, Scarafia LE, Saldou N, Jarnagin K, Swinney DC.

Gene. 1995 Aug 19;161(2):243-8.

PMID:
7665087
37.

Probing for the bradykinin B2 receptor in rat kidney by anti-peptide and anti-ligand antibodies.

Figueroa CD, Gonzalez CB, Grigoriev S, Abd Alla SA, Haasemann M, Jarnagin K, Müller-Esterl W.

J Histochem Cytochem. 1995 Feb;43(2):137-48.

PMID:
7822771
38.

Distribution of bradykinin B2 receptors in target cells of kinin action. Visualization of the receptor protein in A431 cells, neutrophils and kidney sections.

Haasemann M, Figueroa CD, Henderson L, Grigoriev S, Abd Alla S, Gonzalez CB, Dunia I, Hoebeke J, Jarnagin K, Cartaud J, et al.

Braz J Med Biol Res. 1994 Aug;27(8):1739-56.

PMID:
7749366
39.

Bradykinin-B2 receptors in humans and rats: cDNA structures, gene structures, possible alternative splicing, and homology searching for subtypes.

Park J, Freedman R, Bach C, Yee C, Rohrwild M, Kaminishi H, Müller-Esterl W, Jarnagin K.

Braz J Med Biol Res. 1994 Aug;27(8):1707-24.

PMID:
7538372
40.
41.

The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family.

Obernolte R, Bhakta S, Alvarez R, Bach C, Zuppan P, Mulkins M, Jarnagin K, Shelton ER.

Gene. 1993 Jul 30;129(2):239-47.

PMID:
8392015
42.
43.

Physicochemical characterization of recombinant human nerve growth factor produced in insect cells with a baculovirus vector.

Barnett J, Chow J, Nguyen B, Eggers D, Osen E, Jarnagin K, Saldou N, Straub K, Gu L, Erdos L, et al.

J Neurochem. 1991 Sep;57(3):1052-61.

PMID:
1861144
44.

Expression cloning of a rat B2 bradykinin receptor.

McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, Fujisaki J, Aldrich RW, Jarnagin K.

Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7724-8.

45.

Synthetic HIV-2 protease cleaves the GAG precursor of HIV-1 with the same specificity as HIV-1 protease.

Wu JC, Carr SF, Jarnagin K, Kirsher S, Barnett J, Chow J, Chan HW, Chen MS, Medzihradszky D, Yamashiro D, et al.

Arch Biochem Biophys. 1990 Mar;277(2):306-11.

PMID:
2178555
46.

1,25-Dihydroxyvitamin D3-stimulated mRNAs in rat small intestine.

Kessler MA, Lamm L, Jarnagin K, DeLuca HF.

Arch Biochem Biophys. 1986 Dec;251(2):403-12.

PMID:
3800375
47.

Purification and characterization of the receptor for insulin-like growth factor I.

Morgan DO, Jarnagin K, Roth RA.

Biochemistry. 1986 Sep 23;25(19):5560-4.

PMID:
2946318
48.

Metabolism and pharmacokinetics of 24,25-dihydroxyvitamin D3 in the vitamin D3-replete rat.

Jarnagin K, Zeng SY, Phelps M, DeLuca HF.

J Biol Chem. 1985 Nov 5;260(25):13625-30.

49.

The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.

Ebina Y, Ellis L, Jarnagin K, Edery M, Graf L, Clauser E, Ou JH, Masiarz F, Kan YW, Goldfine ID, et al.

Cell. 1985 Apr;40(4):747-58.

PMID:
2859121
50.

1,25-Dihydroxyvitamin D3 normalizes maternal food consumption and pup growth in rats.

Brommage R, Jarnagin K, DeLuca HF.

Am J Physiol. 1984 Mar;246(3 Pt 1):E227-31.

PMID:
6546643

Supplemental Content

Loading ...
Support Center